PMID- 2823014
OWN - NLM
STAT- MEDLINE
DCOM- 19871207
LR  - 20131121
IS  - 0887-6924 (Print)
IS  - 0887-6924 (Linking)
VI  - 1
IP  - 2
DP  - 1987 Feb
TI  - A trial of recombinant alpha 2 interferon in the myelodysplastic syndrome: II. 
      Characterization and response of granulocyte and platelet dysfunction.
PG  - 111-5
AB  - Because qualitative neutrophil and platelet dysfunction is an important 
      concomitant of the myelodysplastic syndrome, functional studies were performed 
      prospectively of cells from eight patients with myelodysplastic syndrome 
      undergoing treatment with recombinant alpha 2 interferon. Neutrophil studies 
      performed included myeloperoxidase release and superoxide anion generation, 
      measured spectrophotometrically, in response to stimulation by 
      phorbol-12-myristate-13-acetate, opsonized zymosan, and the chemotactic peptide 
      formyl-methionyl-leucyl-phenylalanine (fMLP), respectively. The most consistently 
      abnormal of these tests was the fMLP-stimulated superoxide anion generation, 
      which was low in six of seven patients tested. Mean results with this test were 
      significantly lower than controls (mean +/- SD = 5.11 +/- 2.41 nmol/10(6) patient 
      cells vs. 10.14 +/- 3.02 with normal cells, p less than 0.001). No significant 
      change was noted following 2 or 8 weeks of interferon therapy. Because of the 
      severe thrombocytopenia prevalent in myelodysplastic syndrome, fewer platelet 
      studies were feasible. One patient, however, exhibited normal platelet numbers 
      but markedly decreased aggregation in response to arachidonic acid, epinephrine, 
      and collagen. After 4 weeks of treatment, this patient's platelet aggregation was 
      noted to be normal. Platelets from two patients were purified by gel filtration, 
      and the ATP/ADP ratios were determined by HPLC. Pretreatment ATP/ADP ratio of one 
      patient was 4.85 (normal = 1.85 +/- 0.28) which declined to 3.27 on treatment and 
      then returned to 4.80 following a 14-day period off treatment. Another patient, 
      also with elevated ATP/ADP, exhibited a smaller decline during a treatment cycle. 
      From these studies it was concluded that fMLP-stimulated superoxide generation 
      may be a sensitive marker for neutrophil dysfunction in the myelodysplastic 
      syndrome. No evidence was found for improvement of neutrophil dysfunction 
      following alpha 2 interferon treatment. alpha 2 interferon, however, may 
      sometimes have beneficial effects upon platelet dysfunction.
FAU - Elias, L
AU  - Elias L
AD  - Cancer Center, University of New Mexico School of Medicine, Albuquerque.
FAU - Van Epps, D E
AU  - Van Epps DE
FAU - Smith, K J
AU  - Smith KJ
FAU - Savage, B
AU  - Savage B
LA  - eng
GR  - 3 MO1 RR00997/RR/NCRR NIH HHS/United States
GR  - HL24336/HL/NHLBI NIH HHS/United States
GR  - HL31950/HL/NHLBI NIH HHS/United States
GR  - etc.
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (Interferon Type I)
RN  - 0 (Receptors, Formyl Peptide)
RN  - 0 (Receptors, Immunologic)
RN  - 11062-77-4 (Superoxides)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 8L70Q75FXE (Adenosine Triphosphate)
RN  - EC 1.11.1.7 (Peroxidase)
SB  - IM
MH  - Adenosine Diphosphate/blood
MH  - Adenosine Triphosphate/blood
MH  - Blood Platelets/*physiology
MH  - Chemotaxis, Leukocyte
MH  - Granulocytes/*physiology
MH  - Humans
MH  - Interferon Type I/*therapeutic use
MH  - Myelodysplastic Syndromes/physiopathology/*therapy
MH  - Peroxidase/metabolism
MH  - Platelet Aggregation
MH  - Prospective Studies
MH  - Receptors, Formyl Peptide
MH  - Receptors, Immunologic/physiology
MH  - Superoxides/metabolism
EDAT- 1987/02/01 00:00
MHDA- 1987/02/01 00:01
CRDT- 1987/02/01 00:00
PHST- 1987/02/01 00:00 [pubmed]
PHST- 1987/02/01 00:01 [medline]
PHST- 1987/02/01 00:00 [entrez]
PST - ppublish
SO  - Leukemia. 1987 Feb;1(2):111-5.